{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:23:27Z","timestamp":1767612207905,"version":"3.41.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2017,2,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Aromatase inhibitors are established breast cancer chemoprevention interventions. However, nonadherence remains a significant challenge. We investigated the association between worsening menopause-specific quality of life, baseline participant characteristics, and early treatment discontinuation within the Mammary Prevention.3 (MAP.3) breast cancer prevention trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the MAP.3 randomized, placebo-controlled trial evaluating exemestane, participants completed the Menopause-Specific Quality of Life Questionnaire (MENQOL) at entry and at 6 months. Multivariable log-binomial regression was used to assess the associations of baseline participant characteristics and clinically meaningful worsening in menopause-specific quality of life (QOL) with treatment discontinuation at 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 4,501 participants eligible for this analysis, 724 (17%) discontinued assigned treatment within the first year of random assignment of treatment (19% of the exemestane group and 13% of the placebo group). Between 19% and 35% of women experienced a clinically meaningful worsening in the vasomotor, sexual, physical, and psychosocial domains of the MENQOL within 6 months of treatment initiation. Regardless of receiving exemestane or not, experiencing a worsening in any MENQOL domain or, especially, overall menopause-specific QOL, was associated with early treatment discontinuation (relative risk, 1.79; 95% CI, 1.53 to 2.10 for overall worsening). Assignment to exemestane, having a smoking history, and current employment also were significantly associated with early discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Negative changes in menopause-specific QOL influence a woman\u2019s decision to stop chemoprevention therapy. Attention to such symptoms may improve QOL and potentially improve chemoprevention adherence.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2016.68.8895","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T23:03:05Z","timestamp":1487199785000},"page":"629-635","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":16,"title":["Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial"],"prefix":"10.1200","volume":"35","author":[{"given":"Olivia","family":"Meggetto","sequence":"first","affiliation":[{"name":"Olivia Meggetto, Dongsheng Tu, and Harriet Richardson, Queen\u2019s University; Dongsheng Tu and Harriet Richardson, Canadian Cancer Trials Group, Kingston, Ontario; Elizabeth Maunsell, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada; Rowan Chlebowski, Harbor-University of California, Los Angeles, Medical Center, Torrance, CA; Paul Goss, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Maunsell","sequence":"additional","affiliation":[{"name":"Olivia Meggetto, Dongsheng Tu, and Harriet Richardson, Queen\u2019s University; Dongsheng Tu and Harriet Richardson, Canadian Cancer Trials Group, Kingston, Ontario; Elizabeth Maunsell, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada; Rowan Chlebowski, Harbor-University of California, Los Angeles, Medical Center, Torrance, CA; Paul Goss, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowan","family":"Chlebowski","sequence":"additional","affiliation":[{"name":"Olivia Meggetto, Dongsheng Tu, and Harriet Richardson, Queen\u2019s University; Dongsheng Tu and Harriet Richardson, Canadian Cancer Trials Group, Kingston, Ontario; Elizabeth Maunsell, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada; Rowan Chlebowski, Harbor-University of California, Los Angeles, Medical Center, Torrance, CA; Paul Goss, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Goss","sequence":"additional","affiliation":[{"name":"Olivia Meggetto, Dongsheng Tu, and Harriet Richardson, Queen\u2019s University; Dongsheng Tu and Harriet Richardson, Canadian Cancer Trials Group, Kingston, Ontario; Elizabeth Maunsell, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada; Rowan Chlebowski, Harbor-University of California, Los Angeles, Medical Center, Torrance, CA; Paul Goss, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Tu","sequence":"additional","affiliation":[{"name":"Olivia Meggetto, Dongsheng Tu, and Harriet Richardson, Queen\u2019s University; Dongsheng Tu and Harriet Richardson, Canadian Cancer Trials Group, Kingston, Ontario; Elizabeth Maunsell, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada; Rowan Chlebowski, Harbor-University of California, Los Angeles, Medical Center, Torrance, CA; Paul Goss, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Richardson","sequence":"additional","affiliation":[{"name":"Olivia Meggetto, Dongsheng Tu, and Harriet Richardson, Queen\u2019s University; Dongsheng Tu and Harriet Richardson, Canadian Cancer Trials Group, Kingston, Ontario; Elizabeth Maunsell, Centre de Recherche du Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada; Rowan Chlebowski, Harbor-University of California, Los Angeles, Medical Center, Torrance, CA; Paul Goss, Massachusetts General Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09962-2"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk050"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103507"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62292-8"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv590"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20004"},{"key":"B10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.20452\/pamw.2190","volume":"124","author":"Chlebowski RT","year":"2014","journal-title":"Pol Arch Med Wewn"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-11-0380"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520250075037"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8651(18)30627-1"},{"key":"B14","first-page":"1367","volume":"128","author":"Schipper H","year":"1983","journal-title":"Can Med Assoc J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.2483"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.06.015"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(96)01038-9"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.10.017"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4065\/77.4.371"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015276414526"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0007"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv365"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-11-0172"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-015-0647-2"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh168"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/01.GME.0000163869.89878.D9"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2016.68.8895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T11:42:08Z","timestamp":1749987728000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2016.68.8895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,20]]}},"alternative-id":["10.1200\/JCO.2016.68.8895"],"URL":"https:\/\/doi.org\/10.1200\/jco.2016.68.8895","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"subject":[],"published":{"date-parts":[[2017,2,20]]},"assertion":[{"value":"2017-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}